Dec 17, 2014
FDA gives green light to Novartis acromegaly drug
FDA gives green light to Novartis acromegaly drug
Regulators in the USA has approved a long-acting release of Novartis’ Signifor as a treatment for acromegaly.
The Food and Drug Administration has approved Signifor LAR (pasireotide) for the treatment of patients with acromegaly who have had an inadequate response to surgery or for whom the latter is not an option. The thumbs-up comes a month after the European Medicines Agency approved the drug,…
View On WordPress